Niche pharma firm Quantum Pharma says it is on target to meet market expectations after taking action to tighten its focus.
The Burnopfield pharmaceutical developer , manufacturer and supplier issued a trading update for the year ended January 31 2017, saying unaudited group adjusted EBITDA for the year is expected to be in line with market expectations.
Quantum Pharma plc (LON:QP), the service-led niche pharmaceutical developer and supplier to the health and care sectors, has reported its Preliminary financial results for the 12 months to January 31, 2017. Net sales grew by 28%
County Durham based Quantum Pharma has bolstered its executive team with the help of business advisers UNW. The niche pharmaceutical developer and manufacturer, which supplies a range of innovative products to wholesalers, retailers and hospitals, approached
Quantum Pharma plc (LON:QP), the service-led niche pharmaceutical manufacturer, developer and supplier to the health and care sectors, has released a pre-close trading update this morning. Zeus Capital said: The Board has indicated that adjusted EBITDA
Quantum Pharma Plc (AIM: QP.), the service-led niche pharmaceutical developer, manufacturer and supplier to the health and care sectors, announces that on 3 January 2017 the Company was notified that Gerard Murray, Quantum’s Chief Financial Officer
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Quantum Pharma plc 2 Reason for the notification (please tick the
Quantum Pharma plc (AIM: QP.) announced this morning a proposed fundraising up to £15 million, by way of the conditional placing of up to 44,117,647 Placing Shares at a price of 34 pence per share with
Zeus Capital’s Gary Waanders discusses Quantum Pharma PLC in this exclusive interview with DirectorsTalk
Quantum Pharma Plc (LON:QP) is the topic of conversation when Dr Gary Waanders the Director of Healthcare Research at Zeus Capital caught up with DirectorsTalk to discuss interim results. Gary explains the warning on profits expectations
Chris Rigg, Chief Financial Officer and Acting Chief Executive Officer of Quantum Pharma LON:QP., commented: “The core specials business is performing well and launches from the Niche Pharmaceuticals pipeline are being brought to market largely in
Andy Scaife, CEO of Quantum Pharma, commented: “We are excited to be making available the first product in the Mucodis(R) range. This range has the potential to make a difference for patients living with the side
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Quantum Pharma Plc 2. Reason for the notification (please tick
Quantum Pharma Plc (AIM:QP.), the growing, service-led niche pharmaceutical manufacturer, developer and supplier to the health and care sectors, has told DirectorsTalk about the appointment of Nicola Massey as the new Managing Director of its Niche
Quantum Pharma Plc (AIM: QP.), the growing, service-led niche pharmaceutical manufacturer, developer and supplier to the health and care sectors, has today given DirectorsTalk its half year results for the six months to 31 July 2015,
Andrew Scaife, Chief Executive Officer of Quantum Pharma Plc (LON:QP.), said: “The first six months of the financial year have been a busy period at Quantum Pharma. We successfully completed the strategic acquisitions of Lamda and
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.